DEF: Whitehawk Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Whitehawk Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation advisory vote, and auditor ratification.

Summary

• Whitehawk Therapeutics will hold its 2025 Annual Meeting of Stockholders online on June 11, 2025, at 10:00 a.m. Pacific Time.
• Stockholders of record as of April 17, 2025, are entitled to vote at the meeting.
• The agenda includes the election of three Class II directors for terms ending in 2028, an advisory vote on executive compensation, and ratification of BDO USA, P.C. as the independent accounting firm for the fiscal year ending December 31, 2025.
• The board recommends voting 'FOR' the election of director nominees and the ratification of the accounting firm.
• The company's common stock outstanding as of April 17, 2025, was 46,784,618 shares.
• Proxy materials are available online at www.proxyvote.com, with the Notice of Availability first being mailed on or about April 28, 2025.
• The company divested Aadi Subsidiary, Inc. and the FYARRO Business on March 25, 2025, and changed its name from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The information is presented in a clear and organized manner, and the board recommends voting in favor of the proposals, suggesting a positive outlook from management's perspective.

Positives

• The company is following good corporate governance practices by seeking stockholder ratification of the independent accounting firm.
• The board is comprised of a majority of independent directors.
• The company has established various committees (Audit, Compensation, Nominating and Corporate Governance) to oversee key aspects of its operations and governance.
• Stockholders have multiple avenues to vote and participate in the annual meeting.

Negatives

• Karin Hehenberger will not be nominated for re-election, reducing the board size to nine members.

Risks

• The company faces risks related to its financial condition, development activities, operations, strategic direction, and intellectual property, as detailed in its SEC filings.
• The company's success depends on its ability to manage these risks effectively.

Future Outlook

The document outlines the agenda for the upcoming annual meeting and provides information relevant to voting decisions, but does not contain specific forward-looking statements about the company's future financial performance or strategic direction.

Management Comments

• David Lennon, Ph.D., President & Chief Executive Officer: 'Your investment and continuing interest in the Company are very much appreciated.'

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to vote on key matters such as director elections, executive compensation, and auditor selection.

Comparison to Industry Standards

• The proxy statement adheres to SEC regulations and Nasdaq listing requirements, which is standard practice for publicly traded companies.
• The virtual format of the annual meeting is increasingly common, reflecting a trend towards greater accessibility and cost-effectiveness.
• The company's board structure, with a majority of independent directors and established committees, aligns with best practices in corporate governance.
• The disclosure of related-person transactions and the existence of a related-person transaction policy are consistent with regulatory requirements and promote transparency.

Related Party Transactions

• Certain directors, executive officers, and 5% holders participated in the PIPE Financing, purchasing shares of common stock and/or pre-funded warrants.
• The company entered into support agreements with directors, executive officers, and certain stockholders to vote in favor of the Divestiture and PIPE Financing.

Stakeholder Impact

• Stockholders have the opportunity to vote on key matters affecting the company's governance and direction.
• The outcome of the votes on director elections and executive compensation could impact the company's leadership and management incentives.
• The ratification of the independent accounting firm ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 11, 2025, and announce the results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, Whitehawk Therapeutics, Stockholders